Target intelligence / Profile preview

Target protein recruited for degradation (Protein of Interest) (POI)

Target
POI
Molecular classification
Other
01

Overview

The term "Target protein recruited for degradation" refers to a Protein of Interest (POI) that is selectively targeted for elimination by the cell's internal disposal systems, primarily the ubiquitin-proteasome system (UPS) (Sun et al., 2019). This process is typically mediated by Targeted Protein Degradation (TPD) molecules, such as Proteolysis Targeting Chimeras (PROTACs) or molecular glues, which act as bridges between the POI and an E3 ubiquitin ligase (Bekes et al., 2022). Once recruited, the POI undergoes polyubiquitination, signaling the 26S proteasome to degrade the protein into small peptides (Bondeson et al., 2015). This therapeutic strategy is revolutionary because it allows for the targeting of proteins that lack traditional small-molecule binding pockets, often referred to as "undruggable" (Mullard, 2019). By completely removing the protein rather than just inhibiting its activity, TPD can achieve more potent and prolonged biological effects and potentially overcome resistance mechanisms seen with traditional inhibitors (Cromm & Crews, 2017). Common disease areas for this approach include oncology, where proteins like the androgen receptor or BRD4 are frequently targeted (Wang et al., 2020).

Other names
Protein of InterestPOINeosubstrateDegradation targetTargeted protein
02

Mechanism of action

Targeted protein degradation (TPD) involving the recruitment of an E3 ubiquitin ligase to a protein of interest, leading to polyubiquitination and subsequent degradation by the 26S proteasome, or via lysosomal/autophagic pathways.

03

Biological functions

Other
04

Disease associations

CancerNeurodegenerative diseaseInflammationInfection
05

Safety considerations

Off-target degradation of non-intended proteinsHook effect (loss of efficacy at high concentrations)Competition for E3 ligase machineryPotential for systemic toxicity from protein depletion
06

Interacting drugs

PROTACs (e.g., ARV-110, ARV-471)

4 more in the full profile.

07

Biomarkers

Target protein concentration (DC50/Dmax)Ubiquitination of POIDownstream pathway modulationCellular viability

Beyond the preview

Go deeper on Target protein recruited for degradation (Protein of Interest) (POI).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Target protein recruited for degradation (Protein of Interest) (POI).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call